YS ON 001

Drug Profile

YS ON 001

Alternative Names: Polyinosinic-polycytidylic acid/inactivated rabies virus; YS-ON-001

Latest Information Update: 31 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yisheng Biopharma
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action B cell stimulants; Cytokine stimulants; Dendritic cell stimulants; Immunomodulators; Macrophage modulators; Natural killer cell stimulants; Regulatory T lymphocyte inhibitors; Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Clinical Phase Unknown Cancer

Most Recent Events

  • 30 Aug 2017 Pharmacodynamics data from preclinical studies in Solid tumours released by Yisheng Biopharma
  • 01 Apr 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Singapore (IM) (NCT03131765)
  • 24 Oct 2016 Clinical trials in Cancer in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top